SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending as the community highlights its bullish chart structure and potential for a breakout, with some drawing comparisons to Shiba Inu. Active discussions revolve around accumulation patterns, strong support levels, and growing awareness of the token. Some users suggest a breakout is coming soon.

DMTC or DIAMOND The Cat Coin is a viral meme coin on Solana Blockchain, Based in Thailand and Global and Based on a true story about my lovely cat(DIAMOND) and made by love, I just want my cat to be immortal in this whole world until I die that's a first idea of this project start. We're start from $2,000 Market cap and hit All time high at $10.9 million, please come to check our project and let's DMTC get list on Coingecko to let's everyone in this whole world know DMTC.

DIAMOND The Cat Coin

DIAMOND The Cat Coin ($DMTC.X) is gaining attention, with community members highlighting its potential for a significant breakout. Discussions center on the building momentum and anticipation of a 'roar' or 'explosion' as the chart shows signs of increasing pressure. Some users suggest it could be the next gem in the crypto space.

About Cartesi (CTSI)  Cartesi enables developers to build appchain rollups with any code, while benefiting from the security of Ethereum. It bridges the gap between traditional software and blockchain by bringing decades of mature operating systems, programming languages, libraries, and tools to decentralized applications.  Cartesi aims to provide the technological foundation from which builders, entrepreneurs, and projects will develop decentralized applications. The Cartesi technology suite is currently comprised of:  Cartesi Rollups: Cartesi Rollups is an app-specific execution environment that can be deployed as a L2, L3, or as sovereign rollups. The combination of an Optimistic Rollups framework and the Cartesi Machine Emulator enables the development of smart contracts and dApps using any package or library that is available for Linux. This allows developers to break free from the scalability limitations of the Ethereum Virtual Machine (EVM), and brings the rise of a new blockchain era to handle real-life and complex use cases.  Cartesi Machine: A RISC-V-based virtual machine (altVM) running Linux OS, enabling complex computations and seamless dApp development by expanding the design space and leveraging 40 years of software programming advancements.  CartesiScan: Cartesiscan is the explorer used for viewing blockchain transactions on Cartesi appchain rollups.  Cartesi Explorer: The Cartesi Explorer is a product that allows CTSI users to interact with the governance system and stake CTSI.  Fraud Proof System - DAVE (following PRT): Dave is a permissionless, interactive fraud-proof system. Cartesi’s algorithm further optimizes the fraud proof mechanism to achieve the best balance between security, decentralization, and activity.  What Makes Cartesi Unique  The infrastructure of the internet took 40 years, billions of hours of work, and trillions of dollars to build. With Cartesi, developers gain access to these decades of meticulously refined operating systems, programming languages, software libraries, and tools, paving the way for the next generation of blockchain applications.  Cartesi empowers Ethereum rollups with real-world software and strong guarantees.  Cartesi designed its own Optimistic Rollups framework embedding its own non-EVM virtual machine based on RISC-V.  Leverage decades‑proven software ecosystems: The Cartesi Machine enables full Linux and RISC‑V stack execution in a composable, verifiable rollup environment.  Cartesi’s architecture is optimized for app‑specific rollups, providing scalable and secure chains tailored to each dApp’s needs, backed by a state-of-the-art fraud proof system, properly categorized as Stage-2 according to L2BEAT.  Token Utility  Governance: CTSI holders can currently stake their tokens to earn rewards and participate in ecosystem governance.   Validator Marketplace: Applications built on Cartesi need validators to monitor and ensure the trustworthiness of transactions. The Validator Marketplace is a decentralized matchmaking service that connects applications with validation service providers. The Validator Marketplace will leverage the CTSI token as a primary means of incentivization in three important ways:  1. Validators will be required to stake CTSI in order to participate, ensuring performance and honest behavior.  2. CTSI holders will be able to delegate their CTSI to experienced validators, allowing tokenholders to share in validation fees without running their own nodes.  3. Token holders can use their CTSI to “buy” a stake in a dApp’s future growth, signaling support for dApps they believe will succeed. The earlier a backer “gets in” on a dApp, the more they are rewarded as that dApp gains traction.  The Validator Marketplace creates a direct link between Cartesi dApp usage and CTSI token demand, enabling token holders to share in the growth and success of the ecosystem.

Cartesi

Cartesi is gaining attention, with community members highlighting its potential to revolutionize Web3 development by bringing Linux to the blockchain. Discussions revolve around the project's strong fundamentals, long-term development goals, and recent strategic integrations. Some users are speculating on potential price targets amid excitement around altcoins.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as community members discuss its recent surge and potential for further gains, with some comparing it to other high-performing tokens. The conversations highlight its strong backers and unique features, including access to real-world assets, which are contributing to bullish sentiment. Traders are actively analyzing price charts and anticipating the next leg up, with some setting ambitious price targets.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as the top meme coin on the Bitcoin blockchain, with the community emphasizing its fair distribution and strong grassroots support. Discussions highlight its potential as a Bitcoin-native meme, contrasting it with Ethereum and Solana-based alternatives. The community refers to itself as the DOG Army.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the Square and Cash App segments. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. It also includes Cash App Card, which is linked to customer stored balances that customers can use to pay for purchases or withdraw funds from an ATM. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

XYZ is trending due to its upcoming inclusion in the S&P 500, generating community buzz and analyst upgrades. Community members are actively discussing the potential for a sustained rally, with some pointing to the stock's previous struggles and hoping this marks a turnaround. Broader conversations include its valuation relative to peers like $PYPL and its exposure to the crypto market.

MYX Finance

MYX.X is seeing increased discussion around its volatility and potential for both upward and downward price movement. Some traders are pointing to token unlocks and building short positions, while others suggest it has strong continuation potential. The conversation includes comparisons to other recently successful tokens, like AVNT.X, with some anticipating similar gains.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillow is trending as investors assess its valuation relative to competitors like Opendoor, particularly in light of falling mortgage rates and housing market data. Community discussions include Zillow's potential in rentals and its future performance amid shifts in interest rates. Some investors are also closely monitoring the potential impact of a copyright lawsuit from CoStar.

Memecoin on Injective taken over by the community.

Nonja

Nonja is trending as community members highlight its strong performance within the Injective ecosystem and anticipate significant gains. Discussions emphasize the meme coin's unique attributes, including its engaged community, substantial liquidity, and connection to the growing Injective ($INJ.X) blockchain. The community believes $NONJA.X is poised for substantial growth, potentially outperforming other meme coins.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending as the community discusses the upcoming expiration of the KYC grace period and potential impacts on tokenomics. There's speculation around unverified coins returning to the mining pool, potentially decreasing the circulating supply. Some users are also pointing to upcoming events like 'Pi-two day' as potential catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Options Traders Betting on a Big Move in BCRX Stock?

Investors need to pay close attention to BioCryst Pharmaceuticals stock based on the movements in the options market lately.

BioCryst Pharmaceuticals, Inc. (BCRX) is now looking forward to data on its Netherton Syndrome and DME pipeline programs after its second-quarter earnings beat Wall Street expectations on the strong performance of its Orladeyo drug.“Our Netherton Syndrome and DME (diabetic macular edema) pipeline programs remain on track to have some data by the end of the year,” said CEO Jon Stonehouse on the company’s earnings call on Monday. The company is enrolling patients for an early-stage trial of both investigational drugs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BCRX">BCRX</a> is trending in the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_at_11_07_20_AM_png_98d2936188.webp" alt="BCRX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>BCRX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock’s fair valuation is double its current level.<stembedurl>https://stocktwits.com/doublebtx/message/623619202</stembedurl>Another expressed disappointment at the stock’s slow rally.<stembedurl>https://stocktwits.com/coleslaugh/message/623622668</stembedurl>Netherton syndrome is a rare genetic disorder primarily affecting the skin, hair, and immune system, in which patients experience severe skin problems, including redness, scaling, and blistering, as well as hair abnormalities like bamboo hair.DME, meanwhile, is a leading cause of vision loss in people with diabetes. Fluid accumulates in the central part of the eye’s retina, causing swelling and blurry or distorted vision.A company spokesperson said on the call that the firm is looking at data on several endpoints, including the penetration of the drug in the skin, and on potential efficacy endpoints, including itching and healing of the skin with its investigational drug for Netherton syndrome. For the company’s investigational drug for DME, the company is looking at the effect of the drug on the retina and the potential for reducing the swelling in the retina after a dose of the drug.For the second quarter, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biocryst.com/news-releases/news-release-details/biocryst-reports-second-quarter-2025-financial-results-and">reported</a> total revenue of $163.35 million, compared to $109.33 million in the corresponding quarter of 2024, and above an analyst estimate of $149.22&nbsp;&nbsp;&nbsp;&nbsp;million, as per data from Fiscal AI.Orladeyo, the company’s medicine used to prevent attacks of hereditary angioedema (HAE), accounted for a whopping 96% of the company’s total revenue in the quarter. Orladeyo's net revenue in the quarter jumped 45% to $156.8 million.For the full year, the company now expects global net Orladeyo revenue to be between $580 million and $600 million, even when excluding fourth quarter European revenue after the expected closing of the sale of its European business. Biocryst in June said that it has entered into a definitive agreement to sell its European Orladeyo business to Neopharmed Gentili for up to $264 million. Closing of the transaction is expected by early October.The company said that it also remains on track to deliver net income and positive cash flows for the full year 2025.BCRX stock is up by about 12% this year and over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-announces-purchase-of-blade-urban-air-mobility-business/chrXN6wRdTY">Joby Aviation Stock Flies 15% After Company Announces Purchase Of Blade’s Urban Air Mobility Business: Retail’s Not Entirely Convinced</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level

CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year. 

Equity

BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of +400.00% and +9.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts 

ENSG adds Idaho and Texas facilities to its skilled nursing facility and real estate portfolios and earns an opportunity to boost revenues by catering to growing patient volumes. 

Select Medical Expands Presence in Tennessee With Ballad Health Deal

SEM partners with Ballad Health to relocate and expand its Tri-Cities critical illness recovery hospital, boosting care access in Tennessee by being able to treat more patients grappling with serious illnesses. 

BioCryst Pharmaceuticals, Inc. (BCRX) on Friday said that it has entered into a definitive agreement to sell its European Orladeyo business to Italian pharmaceutical company Neopharmed Gentili for up to $264 million.BCRX shares were up by over 4% in the pre-market session, following the news.As per the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biocryst.com/news-releases/news-release-details/biocryst-announces-sale-european-orladeyor-berotralstat-business">agreement</a>, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo. Biocryst is also eligible to receive up to $14 million in future milestone payments.Orladeyo, also known as berotralstat, is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in adults and children 12 years of age and older. Hereditary angioedema (HAE) is a rare genetic disorder causing recurring episodes of severe swelling in various body parts, including the limbs, face, intestinal tract, and airway.<a href="https://stocktwits.com/symbol/BCRX">BioCryst</a> plans to use the proceeds from the transaction to retire all remaining term debt of $249 million from Pharmakon, which will eliminate approximately $70 million of future interest payments.The biotech company expects the transaction to result in at least $50 million in expected annual operating expense savings for BioCryst. It also expects to end 2027 with approximately $700 million in cash and no term debt, marking an increase of $400 million from its previous 2027 net cash guidance.In the first quarter (Q1) of 2025, BioCryst reported Orladeyo net revenue of $134.2 million, marking a growth of 51% year-on-year. Oraledyo revenue, in fact, accounted for about 92% of the company’s overall revenue in the period.However, sales from the U.S. contributed 89.5% of global Orladeyo net revenues in the first quarter, implying the European business accounted for only a small portion.On Stocktwits, retail sentiment around BCRX stayed unchanged within ‘bearish’ territory over the past 24 hours, accompanied by ‘low’ levels of retail chatter.<figure class="image"><img style="aspect-ratio:1250/134;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_7_45_04_AM_png_68794667d1.webp" alt="BCRX's Sentiment Meter and Message Volume as of 7:45 a.m. ET on June 27, 2025 | Source: Stocktwits" width="1250" height="134"><figcaption>BCRX's Sentiment Meter and Message Volume as of 7:45 a.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure>However, a Stocktwits user expressed surprise at the deal and opined that the additional cash makes it easier for the company to find a buyer if that is what it intends to do.<stembedurl>https://stocktwits.com/justfkntrade/message/619211689</stembedurl>Another opined that the deal makes the company an ‘irresistible candy’ with no debt.<stembedurl>https://stocktwits.com/gdesivir/message/619209736</stembedurl>Biocryst had also said in May that it expects to be profitable for the full year 2025, a year ahead of schedule.BCRX stock is up by 28% this year and by about 58% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-slams-eu-as-closed-for-business-after-200-m-fine-warning-of-daily-penalties/chmguP6RRIt">Meta Slams EU As ‘Closed For Business’ After $200M Fine, Warning of Daily Penalties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish

As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up to $14 million in future milestone payments.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Fed policy & rates

Earnings reports

Economic data

Geopolitics & news

What will be the primary driver of the market next week?

Stocktwits

Stocktwits Polls

BCRX is trending as investors discuss its potential acquisition following news of a CEO transition and strong revenue growth, with community members speculating on pipeline developments and strategic moves post-debt repayment. Bullish sentiment is fueled by the company's increasing profitability and potential for new drug approvals, while some express concerns about past stock performance and management decisions. The focus remains on whether BCRX will be acquired or continue as a consolidator of rare disease assets.

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BCRX News

BCRX Biocryst Pharmaceuticals Inc.